Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | 259 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
21.05. | Protagenic Therapeutics sammelt 3,1 Millionen US-Dollar durch Optionsscheine ein | 4 | Investing.com Deutsch | ||
21.05. | Protagenic Therapeutics raises $3.1 million from warrants | 2 | Investing.com | ||
21.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity | 262 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have... ► Artikel lesen | |
20.05. | Pre-market Movers: Eyenovia, Instil Bio, Protagenic Therapeutics, Bon Natural Life, D-Wave Quantum | 668 | AFX News | BEIJING (dpa-AFX) - Pre-market Movers: EYEN, TIL, PTIX, BON, QBTS.The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Eyenovia... ► Artikel lesen | |
19.05. | Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher | 4 | Benzinga.com | ||
19.05. | Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger | 5 | Benzinga.com | ||
19.05. | Protagenic Therapeutics Aktie steigt nach Fusion zur Gründung eines neuroaktiven Pharmaunternehmens | 7 | Investing.com Deutsch | ||
PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
19.05. | Protagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical company | 1 | Investing.com | ||
19.05. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
19.05. | Protagenic Therapeutics merges with Phytanix Bio in all-stock deal | 3 | Investing.com | ||
19.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders | 334 | ACCESS Newswire | NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange... ► Artikel lesen | |
13.05. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
05.05. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 3 | SEC Filings | ||
29.04. | Protagenic Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:14 an | 2 | Investing.com Deutsch | ||
29.04. | Protagenic Therapeutics announces 1-for-14 reverse stock split | 1 | Investing.com | ||
29.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split | 290 | ACCESS Newswire | Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics"... ► Artikel lesen | |
18.04. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | Protagenic Therapeutics, Inc.\new - 10-K, Annual Report | 3 | SEC Filings | ||
24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,552 | -1,17 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
VALNEVA | 2,394 | -4,01 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
BIOFRONTERA | 2,200 | +0,92 % | Biofrontera AG: Verhandlungen mit Biofrontera Inc. gehen kommende Woche weiter | Bad Marienberg (www.anleihencheck.de) - Pressemitteilung der Biofrontera AG vom 26.06.2025:Die Verhandlungen zwischen der deutschen Biofrontera Gruppe und dem US-amerikanischen Unternehmen Biofrontera... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,120 | -11,89 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,480 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,950 | +1,56 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,900 | +2,79 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,464 | -4,55 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,335 | -3,05 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 0,930 | -7,00 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,471 | -0,42 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
EDITAS MEDICINE | 1,843 | +1,49 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
VAXART | 0,441 | -3,67 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen |